GE HealthCare: The Demand Is Just Too Strong To Ignore
GE HealthCare's diverse business model, strong demand, and leadership in key segments position it well for long-term growth, especially with an aging population tailwind. Recent tariff volatility has pressured margins and guidance, but GEHC's global supply chain efficiency and margin recovery potential remain attractive for patient investors. Valuation is compelling at 17x forward PE, with buybacks and robust demand supporting an 18% CAGR outlook to 2029, signaling strong upside potential.
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
BOCA RATON, Fla. , June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp.
GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL
GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.
GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use
GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.
GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech
GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.
GE Healthcare sees tariffs costing $500 million in 2025, then much less next year
GE Healthcare sees bilateral China tariffs accounting for most of the expected tariff cost, or roughly 75%.
GE HealthCare Q1 Earnings & Sales Beat Estimates, Net Margin Rises
GEHC's first-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
GE HealthCare Technologies Inc. (GEHC) Q1 2025 Earnings Call Transcript
GE HealthCare Technologies Inc. (NASDAQ:GEHC ) Q1 2025 Earnings Conference Call April 30, 2025 8:30 AM ET Company Participants Carolynne Borders - Chief Investor Relations Officer Peter Arduini - President and Chief Executive Officer Jay Saccaro - Vice President and Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jason Bednar - Piper Sandler Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan David Roman - Goldman Sachs Joanne Wuensch - Citi Craig Bijou - BofA Securities Anthony Petrone - Mizuho Financial Group Operator Good day, and thank you for standing by. Welcome to the GE HealthCare First Quarter 2025 Earnings Conference Call.
GE HealthCare (GEHC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GE HealthCare Technologies (GEHC) Q1 Earnings and Revenues Top Estimates
GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.90 per share a year ago.
GE HealthCare Results Top Estimates But Firm Cuts Profit Outlook Over Tariffs
GE HealthCare Technologies (GEHC) on Wednesday posted first-quarter results that came in better than analysts had expected, but the former General Electric division lowered its full-year profit outlook because of tariffs.
Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings?
GEHC Q1 results are likely to reflect strong growth in Imaging, Ultrasound, and AI, fueled by robust procedure volumes and global partnerships despite China headwinds.
